Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 18/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15244577 | 0.95 | FGFR3 (0.66) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725977 | 0.91 | FGFR3 (0.51) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725918 | 0.89 | FGFR3 (0.65) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725919 | 0.85 | FGFR3 (0.64) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725782 | 0.85 | FGFR3 (0.48) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244085 | 0.85 | FGFR3 (0.54) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244637 | 0.84 | FGFR3 (0.70) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL18906146 | 0.82 | FGFR3 (0.66) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL17469982 | 0.82 | FGFR3 (0.49) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244539 | 0.81 | FGFR3 (0.52) | FGFR3KCNH2FGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885KCNH2 3097/4885FGFR1 2/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885KCNH2 2907/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.